Arvinas, Inc.
ARVN · Price history
Price at last available close
$7.83
+$0.33 (+4.33%) 1M
2026-10-29
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Arvinas, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men.
How they make money
Arvinas is a clinical-stage biopharmaceutical company that generates revenue primarily through collaboration and licensing agreements with pharmaceutical partners. These arrangements typically involve upfront payments, research funding, and milestone payments contingent upon the successful development and commercialization of its proprietary PROTAC protein degradation therapies.
Products & services
Arvinas develops a new class of drugs based on its proprietary PROTAC Discovery Engine platform, which engineers proteolysis targeting chimeras to degrade disease-causing proteins.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Pharmaceutical and biotechnology companiesSource
Customer concentration
The company's revenue is highly concentrated in a small number of collaboration partners, with Pfizer and Bayer accounting for a significant portion of total revenue for the fiscal year ended December 31, 2025.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party vendors for clinical trial management, drug substance manufacturing, and drug product formulation; specific supplier names are not disclosed.Source
Business relationships & partnerships
- Pfizer Inc. — A strategic collaboration and license agreement for the development and commercialization of ARV-471 (vepdegestrant) for the treatment of patients with ER+/HER2- locally advanced or metastatic breast cancer.Source
- Bayer AG — A research collaboration and license agreement focused on the discovery and development of protein degraders for targets in oncology, cardiology, and gynecology.Source
Competitors
Strengths
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
38
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
48
Weak
Financial Strength
39
Business Quality / Moat
66
Management
49
Growth Quality
56
Risk / Durability
19
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
37
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
51/100
Building Historical Record
Model Score 51/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently moderate.
- •Recent buyback activity is present
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for ARVN
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can ARVN maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can ARVN fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is ARVN likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What future growth or profitability would be needed to justify ARVN's current valuation?
Essential Investment Snapshot
Wall Street Score
38
Opportunity Score
37
Market Cap
$505.2M
P/E Ratio
40.7
EPS
$0.19
52-Week High
$14.51
52-Week Low
$6.97
Beta
1.76
Intrinsic Value
$7.31
Analyst Target
$13.00
Shares Outstanding
64.9M
Total Revenue
$316.7M
Total Debt
$8.2M
Dividend
No current dividend
Liquidation Value / Share
$8.66
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for ARVN
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on ARVN.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary PROTAC Discovery Engine platform.
- +Strategic collaborations with established pharmaceutical companies.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Dependence on collaboration partners for development and commercialization success.
- −History of operating losses and uncertainty of future profitability.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
37
Sep 8, 2026
Change
+0.9
points
Current Score
38
Oct 1, 2026
Category Changes
ARVN increased 0.9 points because Asset improved by 3.3 points, Capital improved by 5 points.
Positive Contributors
- + Asset improved by 3.3 points
- + Capital improved by 5 points
Projected Score
Projected Score
37
Projected Change
-1.2 points
Preliminary comparable-period financial changes suggest decline of approximately 1.2 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Near Fair ValueCurrent Price
$7.83
Model Intrinsic Value
$7.31
Difference
+$0.52
+7.0% vs IV
Margin of Safety
-7.0%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $316.7M | $262.6M | $263.4M | $78.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $11.3M | $5.2M | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $305.4M | $257.4M | $263.4M | $78.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $238.4M | $282.9M | $348.2M | $379.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $85.2M | $89.4M | $165.4M | $100.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $319.5M | $372.3M | $513.6M | $480.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $2.9M | -$75.3M | -$191.7M | -$359.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$14.1M | -$114.9M | -$250.2M | -$401.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $10.1M | -$80.5M | -$198.3M | -$366.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $800K | $300K | $600K | $900K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $9.3M | -$80.8M | -$198.9M | -$367.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $0.19 | $-1.28 | $-2.77 | $-6.62 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 64.80M | 64.90M | 71.90M | 55.50M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 65.70M | 64.90M | 71.90M | 55.50M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$249.7M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$2.58
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-17.2%
Cash Change
-17.9%
Margin Change
+341.1 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Debt reduced
What Weakened
- Cash position declined
Potential Score Impact
Positive indicators included revenue growth, debt levels, net income margin. Pressure indicators included EPS growth, cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 1014.7%. EPS declined 407.1%. Cash declined 17.9%. Total debt declined 17.2%. Net income margin improved by 341.1 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Reasons Why Investors Should Consider Betting on Arvinas Stock
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate
Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Rumor Mill · ARVN
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial